SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: r. peter Dale who wrote (124)	11/20/1997 12:58:00 PM
From: scaram(o)uche	Read Replies (1) of 579

Peter: Tacrine works for mild to moderate AD. Its hepatotox makes it unreasonable to use at higher doses, where the indication is that it would be even more effective. As a result, a number of the world's pharmas are pursuing cholinesterase inhibitors with reduced tox. The link to the Bayer NDA was merely an indication of progress with one of them. MZ posted a heads up, earlier in the thread, to a BioCentury article that described the Bayer effort and others (Shire/Janssen (JNJ), Pfizer/Essai, and Novartis). Here are leads regarding the Pfizer/Essai efforts...... ncbi.nlm.nih.gov ncbi.nlm.nih.gov You're a postdoc. You know how to use Medline. Why spend 10 minutes posting a series of eleaborate questions to me when you can peruse abstracts from the world's literature in the same period of time? While I don't mind acting as a gopher for the naive, I certainly don't want to do such for other scientists, much less for someone who has a neuro background which dwarfs mine. :-) Tacrine and Aricept are effective. I merely stated that the use of cholinesterase inhibitors is a proven approach, and that the 1553A concept might complement such inhibitors. Obligatory SIBI-related comment: The long-term effects of 1508Y in monkeys continues to mystify and fascinate me. Even if it doesn't turn out to be viable for Parkinson's, I suspect that it will be a tool that will place SIBI far ahead on the learning curve with respect to the regulation of neurotrophins by dopamine. Lilly just hired Christian Fibiger as V.P., Neuroscience Research. He possesses expertise on the dopamine regulation of striatal acetylcholine release, and defects in the striatum have become a focus for Alzheimer's. I hope that SIBI will contact him regarding 1508Y........ ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov ncbi.nlm.nih.gov Investors are ignoring the long-term effects of 1508Y in monkeys. I don't understand why they are doing such. Perhaps I'm lost.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next